Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.48 |
| ▸ | SQSTM1 | Q13501 | 1/20 | 0.48 |
| ▸ | SLC40A1 | Q9NP59 | 4/20 | 0.47 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3531526 | 0.86 | SMN1; SMN2 (0.52) | CCR4SMN1; SMN2TSHRLMNAKEAP1 | |
| SCHEMBL3531129 | 0.81 | SLC40A1 (0.61) | SMN1; SMN2TSHRKEAP1NFE2L2SLC40A1 | |
| SCHEMBL29023892 | 0.75 | KDM4E (0.65) | CCR4SMN1; SMN2TSHRLMNAPTGES2 | |
| SCHEMBL8421017 | 0.74 | TSHR (0.46) | SMN1; SMN2TSHRLMNAKEAP1NFE2L2 | |
| SCHEMBL8627627 | 0.73 | KEAP1 (0.56) | SMN1; SMN2LMNAKEAP1NFE2L2SQSTM1 | |
| SCHEMBL38666234 | 0.72 | NPSR1 (0.67) | CCR4SMN1; SMN2TSHRLMNASLC40A1 | |
| SCHEMBL8421215 | 0.72 | ACLY (0.49) | SMN1; SMN2TSHRLMNAKEAP1NFE2L2 | |
| SCHEMBL8419441 | 0.72 | ABCB1 (0.48) | SMN1; SMN2TSHRLMNAKEAP1NFE2L2 | |
| SCHEMBL29023904 | 0.71 | MAPT (0.64) | CCR4SMN1; SMN2TSHRALDH1A1HTT | |
| SCHEMBL21874148 | 0.71 | METAP2 (0.48) | SMN1; SMN2TSHRLMNAKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728002-B2 | Use of pyrrolopyridine compounds for activating PPAR receptors and treatment of conditions involving such receptors | LABORATOIRES FOURNIER S.A. (FR) | 2010-06-01 | — | — | US | disclosed |
| US-20090239856-A1 | Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors | LABORATOIRES FOURNIER S.A. (FR) | 2009-09-24 | — | — | US | disclosed |
| EP-1919474-B1 | PYRROLOPYRIDINE DERIVATIVES AND USE OF SAME AS PPAR RECEPTOR MODULATORS | FOURNIER LAB SA (FR) | 2009-08-05 | — | — | EP | disclosed |
| US-7557122-B2 | Pyrrolopyridine compounds, method of making them and uses thereof | LABORATOIRES FOURNIER S.A. (FR) | 2009-07-07 | — | — | US | disclosed |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LABORATOIRES FOURNIER S.A. (FR) | 2008-08-21 | — | — | US | disclosed |
| EP-1919474-A1 | PYRROLOPYRIDINE DERIVATIVES AND USE OF SAME AS PPAR RECEPTOR MODULATORS | Laboratoires Fournier S.A. (FR) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007026104-A1 | PYRROLOPYRIDINE DERIVATIVES AND USE OF SAME AS PPAR RECEPTOR MODULATORS | LABORATOIRES FOURNIER S.A. (FR) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239856-A1 | Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors | PPARD, PPARA, PPARG | CCR4 3093/4885SMN1; SMN2 3212/4885TSHR 130/4885 |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LIPG, PCSK9, PNLIP | CCR4 3923/4885SMN1; SMN2 2484/4885TSHR 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.